Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Organogenesis Holdings Inc.
Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results
May 25, 2026
Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®
May 24, 2026
Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM
May 20, 2026
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain
May 20, 2026
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026
May 20, 2026